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Poster Session I S241Myeloablative conditioning regimens may cause life threatening
transplant related toxicities in patients with primary immunodefi-
ciency disorders (PID), particularly in patients with co-morbid con-
ditions. We previously reported the outcomes of a phase I study
using nonmyeloablative conditioning in 14 high-risk patients and
demonstrated low transplant related mortality (TRM; 3-year,
23%); however there was a high incidence of chronic GVHD (1-
year 47%). We reasoned that the incidence of GVHD could be re-
duced if marrow was used instead of PBSC; however, previous expe-
rience showed marrow to be associated with a higher risk for
rejection. Therefore our standard nonmyeloablative regimen of
90 mg/m2 fludarabine and 2 Gy total body irradiation (TBI) was
somewhat intensified to include either Campath 1-H, or, for patients
with infections for whom Campath 1-H was contraindicated, an ad-
ditional 2 Gy TBI.
Sixteen patients with PID and significant underlying infections
and/or other co-morbidities were given HLA-matched related
(n5 7) or unrelated (n5 9) marrow grafts following nonmyeloabla-
tive conditioning modified with either Campath 1-H (n5 3) or 4 Gy
TBI (n5 13). All patients were given postgrafting immunosuppres-
sion with MMF and CSP. Of the 15 patients evaluable for engraft-
ment, mixed (50-95%; n5 8) or full (.95%; n5 6) donor
CD3 +T-cell chimerismwas established in 14 patients. Two patients
required a 2nd myeloablative HCT due to graft rejection or loss of
the granulocyte and NK cell components of the graft despite stable
mixed T-cell chimerism. The cumulative incidence of extensive
chronic GVHD at 1 year was 29%. With a median follow-up of 19
(range, 3 – 36) months the 1-year overall survival and TRM were
87% and 14%, respectively. One patient with disseminated CMV
and adenovirus before HCT died from these infections at day +1
and one patient with pre existing renal failure died at day +222
from complications of renal failure. Five patients were not evaluable
for disease response due to less than 100 days of follow-up (n5 2),
2nd HCT (n5 2), or death prior to day 100 following HCT
(n5 1). Eleven patients had improvement in or correction of their
underlying immunodeficiency. Although preliminary, these results
indicate that outcome can be improved for high-risk patients with
PID using a modified nonmyeloablative conditioning regimen and
marrow grafts, resulting in reduction of chronic GVHD, stable do-
nor engraftment, low TRM, and correction of underlying disease
processes.224
CLINICAL OUTCOMES OF PEDIATRIC PATIENTS REQUIRING INTENSIVE
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This is a multi-center, case controlled, retrospective study of the
short-term and 1-year outcomes of children who received intensive
cardiopulmonary (CP) support during theHSCT admission at seven
tertiary care facilities. Intensive CP support was defined as the need
for continuous positive pressure ventilation, dopamine greater than
or equal to10 mcg/kg/min, or the use of other cardiotropic drug.
We compared the outcomes of 94 patients who required intensive
CP care to 282 patients hospitalized during the same period who
did not receive intensive CP support. Demographic and transplant
data are summarized below. Respiratory failure was the most com-
mon indication for CP care (75.5%) followed by sepsis (10.6%), neu-
rologic event (4.3%), cardiac compromise (2.1%), multi-system
organ failure (MSOF) (2.1%), and other causes (5.4%). Acute
GVHD was present in 21% of patients and macroscopic bleeding
in 26% at the onset of CP support. 46% of patients had a pediatric
logistic organ dysfunction score of at least 1 in two organ systems
at the start of CP support. 44% of patients needed noninvasive ven-
tilation (median duration 2 days). Of this 44%, 66% later required
invasive ventilation, 22% successfully discontinued support, and
12% died. 82% of CP patients received invasive ventilation (medianduration 8 days) and 38% died prior to discharge. 50% of patients
needed cardiac medications. The median duration CP support was
18.6 days. 44.7% of patients died prior to discharge from CP sup-
port, 52.1% transitioned to non-intensive CP care, and 3.2% re-
turned to the HSCT unit for palliation. MSOF was the most
common cause of death (51%). 39% of patients who survived initial
CP support needed additional intensive CP care and 58% of these
patients died prior to discharge. Survival to hospital discharge was
37.2% in the CP group and 98.9% in the non-CP group. OS at 1-
year was 32% and 78% in the CP and non-CP groups. The 1-year
overall survival (86% vs. 79%) and disease-free survival (69% vs
72%) of CP and non-CP patients who survived to hospital discharge
were not significantly different. The 1-year relapse rate, incidence of
GVHD, mean FEV1, shortening fraction, and creatinine were not
significantly different between the two groups. The survival rate of
pediatric patients requiring intensive CP support has improved,
but remains suboptimal. No significant difference existed in 1-year
organ function or survival among patients who did or did not receive
intensive CP support.
Demographic and Transplant Data
Case, n5 94 Control, n5 282Age median (months) 67 97
Diagnosis (%)ALL CR1/CR2 5.3/12.8 8.9/17
AML CR1/CR2 7.4/5.3 11/8.5
Metabolic Disease 12.8 8.5
Immunodeficiency 1.7 4.3
Nonmalignant Hematologic
Disease10.6 9.5Solid Tumor 13.8 17.7
Myelodysplasia 2.1 1.8
HLH 6.4 0.7
Lymphoma 4 5
Osteopetrosis 3.2 0.4
JMML 2.1 0.7
Other 5.3 6.5
Autolgous HSCT 18.1 18.4
Allogeneic HSCT 81.9 81.5Donor Source (%)
6/6 Related Donor 14.3 35.8
\ 6/6 Related Donor 9.1 6.6
6/6 Unrelated Donor 26 26.2
\6/6 Unrelated Donor 50.6 31.4225
TARGETED BIOLOGICAL THERAPY FOR HEMOPHAGOCYTIC LYMPHOHIS-
TIOCYTOSIS IN A MURINE DISEASE MODEL
Johnson, T.S.1,2, Terrell, C.E.2, Jordan, M.B.1,2 1Cincinnati Children’s
Hospital Medical Center, OH; 2Cincinnati Children’s Hospital Medical
Center, OH
Hemophagocytic lymphohistiocytosis (HLH) is a rare and usually
fatal hyperinflammatory disorder associated with genetic defects of
CD8 +T cell and NK cell cytotoxic function. Jordan, et al (Blood
2004;104(3):735-43) previously showed that perforin-deficient
(prf-/-) mice infected with lymphocytic choriomeningitis virus
(LCMV) develop a disorder which is essentially identical to human
HLH. In this animal model of HLH, ineffective cytotoxic
CD8 +T cells fail to down-modulate stimulatory signals from anti-
gen presenting cells. Exaggerated T cell responses are responsible
for massive cytokine production, especially interferon-gamma
(IFN-g), which drives systemic macrophage activation and results
in HLH-like disease pathology. Thus, at least three critical events
occur in the pathogenesis of HLH: 1) abnormal increase in antigen
presentation, 2) abnormal increase in CD8 +T cell activation and cy-
tokine secretion, and 3) pathological macrophage activation.
Survival with current standard HLH therapy, consisting of cyto-
toxic chemotherapy (etoposide) and nonspecific immunosuppression
(dexamethasone), is approximately 75% at 8 weeks. Ongoing studies
using ourmurinemodel of HLH indicate that etoposide acts primar-
ily by deleting activated IFNg-producingT cells.While beneficial in
S242 Poster Session Ireducing HLH related immunopathology, this strategy leads to pro-
found iatrogenic marrow and immune suppression, thus greatly in-
creasing the risk of opportunistic infection. With the explosion of
cinically available immunosuppressive agents, there is a critical
need to define which sorts of immune suppression offer the most ef-
fective yet focused treatment for HLH.
In this study, we utilize our animal model of HLH as a preclinical
screen to test the effectiveness of targeted immune suppression using
agents that interfere with interleukin-2 production or signal trans-
duction in T cells. LCMV-infected prf-/- mice experience exagger-
ated symptomaticity, massive elevations in serum IFNg, and
consumptive anemia before becoming moribund. When these mice
are treated with the mTOR inhibitor rapamycin, either alone or in
combination with inhibitors of T cell costimulation (CTLA4-Ig or
anti-CD2), they show improvements in disease severity, survival,
and hemoglobin levels similar to the benefit seen in animals treated
with etoposide monotherapy. We will present data showing the ef-
fects of these agents on the activation of dendritic cells, T cells,
and macrophages in the context of our animal model.226
OUTCOMES AFTER ADDITION OF RABBIT-ATG TO THE STANDARD
BU + CY PREPARATIVE REGIMEN FOR ALLOGENEIC MATCHED SIBLING
DONOR (MSD) HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) FOR HEMOGLOBINOPATHIES IN CHILDREN
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Introduction: Allogeneic HSCT for hemoglobinopathies following
myeloablative conditioning in MSD setting results in excellent out-
comes in children (85-95% 5 year EFS). Though outcomes are en-
couraging, there is still a 7%-10% incidence of graft rejection and
15-20% incidence of GVHD.We proposed the hypotheses, that ad-
ministration of 10 mg/kg dose of rabbit-ATG (Thymoglobulin,
Genzyme, Cambridge, USA) during the peri-transplant period for
MSDHSCT,will lead to partial in-vivoT-cell depletion; eliminating
the risk of rejection andGVHDwhile not increasing the risk of infec-
tions.
Methods: Patients with sickle cell disease (SCD) with sequelae and
transfusion dependent b-thalassemia, underwentMSDHSCT on an
IRB approved study starting Jan, 2003. All patients received iv Busul-
fan (16 mg/kg over 4 days; targeted AUC of 900-1350 mM/mt, based
on 1st dose PK); Cyclophosphamide (50 mg/kg 4 days) and r-ATG
(2.5 mg/kg/day from days -6 to -3). Cyclosporine and standard short
course Methotrexate on days +1, +3 and +6 was given for GVHD
prophylaxis.
Results: 11 patients (9 SCD and 2 b-Thalassemia; 6 females and 5
males) have received the preparative regimen. Median age of patients’
was 4 years (range,18 months-18 years). The r-ATG infusions were
well tolerated with no missed doses. All patients received sibling BM
grafts with the median cell dose of 3.5  108 TNC/kg (range, 1.8-
10.1  108 TNC/kg). All patients developed grade II-III mucositis.
One patient developedmild VOD and one patient had seizures associ-
ated with reversible posterior leuco-encephalopathy syndrome. All pa-
tients engrafted (ANC.0.5 109/L) bymedianof day +15 (range, day
+10 to +23). 2 patients developedCMVreactivations that responded to
treatment. No other viral reactivations or fungal infections were de-
tected. Serial chimerism analysis post-HSCT shows stable donor en-
graftment in all patients. There was no TRM and none of the
patients developed acute GVHD. One patient developed limited
chronic GVHD of the skin. EFS is 100% after a median follow up of
404 days (range, 61-2409 days) with complete resolution of underlying
disease. End organ function is stable and immune reconstitution is
complete in all the patients evaluable.1 year post-HSCT.
Conclusions:Addition of 10 mg/kg dose of rabbit-ATG to the stan-
dard Bu + CYmyeloablative regimen has minimized the incidence of
rejection, acute and chronic GVHD without increasing toxicity or
incidence of infections for MSD HSCT for hemoglobinopathies.227
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Although BMT plays an important role in the therapy of ALL, the
outcome of children transplanted in third remission (CR3) is poorly
defined. We reviewed 155 children, median age 11 years (range, 1-
18), who received an unrelated donor BMT for ALL in CR3 from
1990 to 2005. Median time from diagnosis to first relapse was 35
months, and median time from first to second relapse was 26 months
(range, 4-116). Stem cell sources were bone marrow (n5 115), pe-
ripheral blood stem cells, PBSC (n5 11) or cord blood (n5 29).
BM and PBSC donor-recipient pairs (n5 126) were matched at
HLA-A, B, C and DRB1 (n5 40, 32%), or mismatched at either
one locus (n5 36, 28%) or$ 2 loci (n5 50, 40%). Cord blood do-
nor-recipient pairs (n5 29) were matched at HLA-A, B, DRB1
(n5 1) or mismatched at either one locus (n5 6) or 2 loci
(n5 22). 92% of patients received total-body irradiation (TBI) and
42% received TBI dose .1300 cGy. Graft vs. host disease
(GVHD) prophylaxis was cyclosporine or tacrolimus plus another
agent in 63% of patients. 31% of patients received T-cell depleted
BM grafts and 52% received ATG as part of transplant conditioning
regimen. The cumulative incidence of neutrophil recovery was 95%
(95% CI, 95- 98%). The day-100 cumulative incidence of grade 2-4
acute GVHD was 58% (50-66%) and chronic GVHD at 3-years,
28% (95% CI 21-35%). The risk of chronic GVHD higher in
PBSC recipients (RR 2.85, 95% CI1.18-6.92, p5 0.01). The inci-
dence of non-relapse mortality (NRM) was 19% (95% CI 14-
26%) at 100 days, 41% (95% CI 33-49%) at 1-year and 45% (95%
CI 37-53%) at 5-years. Causes of NRM included graft failure
(2%), GVHD (5%), infection (12%), organ toxicity (21%), second-
ary malignancies (3%) and other causes (6%). 47 patients are alive at
last follow-up, with median follow-up of 6 years. In multivariate
analysis, the interval between first and second relapse was associated
with relapse after BMT. Relapse risks were higher in patients for
whom this interval was #26 months (RR 2.50, 95% CI 1.28-4.76,
p5 0.01). No risk factors were identified for non-relapse mortality.
The 5-year cumulative incidence of relapse was 17% (95% CI 9-
26%) and 34% (95% CI 24-45%) in patients with a second relapse
.26 months and #26 months from their first relapse, respectively.
Corresponding 5-year leukemia-free survival rates were 33% (95%
CI 23-44%) and 26% (95% CI 16-36%). Unrelated donor BMT re-
sults in acceptable disease free-survival in children with ALL in CR3,
especially those experiencing a late second relapse.228
REDUCED INTENSITY CONDITIONING (RIC) WITH FLU-BU-ATG AND AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FROM HLA IDENTICAL DONORS: RELAPSE-FREE SURVIVAL (RFS) OF
42% IN PEDIATRIC PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIG-
NANCIES
Duerst, R.E., Jacobsohn,D.A., Schneiderman, J., Chaudhury, S., Tse,W.,
Kletzel, M. Children’s Memorial Hospital and Northwestern University,
Feinberg School of Medicine, Chicago, IL
RIC regimens prior to allogeneic HSCT diminish potential com-
plications compared with myeloablative therapy. We report the ex-
perience of 31 RIC HSCT for children/adolescents with
hematologic malignancies at high-risk for relapse or complications
of full-intensity conditioning due to disease state, prior myeloabla-
tive HSCT and/or co-morbid conditions. The RIC regimen was
comprised of fludarabine, 180 mg/m2 over 6 days, 2 days of IV bu-
sulfan; and 4 days of ATG (equine or rabbit). Diagnoses included:
ALL (14, $CR3 in 7), AML (5), treatment-related myelodysplastic
